eFFECTOR Therapeutics, Inc.
142 North Cedros Avenue, Suite B
Solana Beach, California 92075
January 31, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Jordan Nimitz
| Re: | eFFECTOR Therapeutics, Inc. |
Registration Statement on Form S-1
File No. 333-262339
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) of eFFECTOR Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:30 p.m. Eastern Time on February 2, 2022, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Matthew Bush at (858) 523-3962 or, in his absence, Anthony Gostanian at (858) 523-3969.
Thank you for your assistance in this matter.
| Very truly yours, | ||
| EFFECTOR THERAPEUTICS, INC. | ||
| By: | /s/ Michael Byrnes | |
| Michael Byrnes | ||
| Chief Financial Officer and Secretary | ||
| cc: | Stephen T. Worland, Ph.D., eFFECTOR Therapeutics, Inc. |
Cheston Larson, Latham & Watkins LLP.
Matthew T. Bush, Latham & Watkins LLP
Anthony Gostanian, Latham & Watkins LLP
